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Abstract 
There are thought to be many different causes that can lead to the development of 
infertility in females. Many of the causes for this condition present themselves 
before birth, which can predetermine a woman’s fertility capability before she is 
even born. The complex process of germ cell development possesses possibilities 
for error and malfunction that can have permanent, lasting effects on a developing 
fetus. The process of oocyte development is initiated when primordial germ cells 
migrate to the embryotic gonad and begin dividing mitotically. As mitosis 
proceeds, the process of cytokinesis does not go to completion, which maintains 
the cells in cysts. The fundamental process of cyst breakdown occurs, in 
conjunction with apoptosis, in order to separate cysts into individual oocytes 
surrounded by a number of granulosa cells, known as primordial follicles. The 
success of the process of cyst breakdown is thought to be a valuable determinant 
of the overall pool of viable primordial follicles that could be used by a female for 
fertilization in the future. This developmental process is well conserved across 
mammalian species, such as mice and humans.  
     
Hormones are known to play a role in the process of germ cell development via 
various signaling pathways. Abundant research has already been conducted to 
investigate the role of estrogen in this developmental process, specifically 
exploring the hormone’s ability to inhibit cyst breakdown. Similar research has 
demonstrated progesterone’s ability to inhibit cyst breakdown, as well, but much 
more is yet to be investigated about this steroid hormone. Although specific 
progesterone signaling receptors, such as progesterone receptor membrane 
component 1 (PGRMC1) and PGRMC2, and proteins, such as the plasminogen 
activator inhibitor 1 RNA-binding protein (PAIRBP1), have been identified, their 
regulatory functions and interactions within their prospective signaling pathways 
have yet to be well researched. In this study, we investigated where PGRMC1, 
PGRMC2 and PAIRBP1 were expressed in the fetal and neonatal mouse ovary 
via immunocytochemistry. We also investigated when PGRMC1, PGRMC2 and 
PAIRBP1 were most strongly expressed in the mouse ovary across germ cell 
development via western blotting.  
     
The results demonstrate that the expression of PGRMC1 and PAIRBP1 localize to 
the same cells within the mouse ovary, but exhibit different levels of expression 
across fetal and neonatal mouse development. In regards to PGRMC2, the results 
reveal a complete lack of expression of this membrane receptor in the mouse 
ovary at any time throughout the process of germ cell development. In order to 
validate and expand on these results future studies will need to be conducted to 
gain more information about the independent and interactive functions of 
PGRMC1, PGRMC2 and PAIRBP1 in germ cell development.        
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Executive Summary 
 
It may be difficult to believe, but reproductive development in mammals 
begins while the developing fetus is still in utero. At this time, a female will go 
through a complex process in which all of her oocytes will be produced and 
maintained in her ovaries. This is a critical mammalian characteristic for females, 
considering that they are not capable of producing any more oocytes beyond this 
developmental stage. Once the process of oocyte development is complete, the 
pool of oocytes will remain dormant until a female reaches reproductive maturity 
and is capable of releasing a viable egg for fertilization. However, the process of 
fertilization is not always successful and if a woman experiences difficulty 
conceiving a child for an extended period of time she could be considered 
infertile. There are various factors that can contribute to or cause infertility, with 
one of the main considerations being that a dysfunction in the process of oocyte 
development while in utero could have a prolonged effect on a woman’s fertility.  
The process of oocyte development, also known as germ cell 
development, is very complex in nature, involving a wide variety of mechanisms 
and signaling pathways in order to proceed normally. It is known that several 
steroid hormones play an integral role in mediating this process, by binding to 
specific receptors that will activate corresponding pathways that will carry the 
signal until it reaches its destination and the intended response is elicited. 
Estrogen is a hormone that has been thoroughly researched and is known to be 
involved in the process of oocyte development. However, research has also 
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demonstrated that exposure to excess levels of this hormone can cause a glitch in 
the process, as well. Excess levels of estrogen in the developing ovary can lead to 
a deficit in the final number of viable oocytes that a female fetus can possess for 
future reproductive purposes.  
Progesterone is another hormone that is known to play a role in the 
process of oocyte development, but the information that is available regarding the 
mechanisms and pathways through which progesterone is transmitted is 
staggeringly less than what is available on estrogen. Some previous research has 
shown that exposure to excess levels of progesterone can have a similar effect that 
estrogen has on the developing oocytes. Still, considering how much less is 
known about progesterone than estrogen, this research focuses on learning more 
about the role of progesterone throughout oocyte development, specifically 
looking at three components of progesterone signaling pathways. We wanted to 
concentrate on the progesterone receptor membrane component 1 (PGRMC1) 
receptor, PGRMC2 receptor and the plasminogen activator inhibitor 1 RNA-
binding protein (PAIRBP1), which all play a role in the progesterone signaling 
pathway, but are in desperate need of further investigation.   
Since the process of oocyte development is reasonably similar in mice and 
humans, mice were used as the model organism for this research. Male and 
female mice were mated each the beginning of each week and female mice were 
checked for vaginal plugs each day prior in order to determine the exact date on 
which gestation began. Fetal mice at 15.5 days post coitum (dpc) and 17.5 dpc, 
also known as days after conception, and neonatal pups at post-natal day (PND) 1, 
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PND 3 and PND 5 were dissected in order to obtain their ovaries for various 
experiments.  
The fetal and neonatal mouse ovaries were used for two main 
experimental techniques, one of which was immunocytochemistry, or ovary 
staining. This process involved treating the dissected ovaries with a primary 
antibody that would bind to either the receptor or protein of interest that is thought 
to be expressed in the tissue. The ovaries were then treated with a secondary 
antibody, containing a fluorescent tag, which would bind to the primary antibody. 
The ovaries were also treated with propidium iodide, which would stain the nuclei 
of all of the cells in the tissue. Once the staining procedure was complete, the 
ovaries were transferred to a slide and were viewed using the confocal 
microscope. A confocal microscope is a type of microscope that uses lasers that 
are specific to the wavelength at which the tag on a secondary antibody fluoresces 
to infiltrate material on a slide. Since the primary-secondary antibody complex is 
bound to the receptor or protein of interest, it is possible to view the expression of 
the given molecule within the mouse ovary using the confocal microscope and to 
take images in order to compare expression and localization patterns across 
different stages of oocyte development. Another experimental technique used for 
this research was western blotting, which serves to identify specific proteins 
within a sample. Dissected ovaries were homogenized in solution, where they 
were called ovary extracts. The extracts from different fetal and neonatal ages 
were loaded into wells on a gel in chronological order. The molecular components 
of the extracts were then separated by molecular size as they were pushed down 
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the gel by an electric current; a process called gel electrophoresis. The results 
from the gel were then transferred to a membrane, which was incubated with a 
primary and secondary antibody that bind in the same manner as discussed with 
immunocytochemistry. The primary-secondary antibody complex allowed the 
receptor/protein of interest to be detected as bands on the membrane. Whereas 
any insignificant molecules found in the extracts were suppressed using a specific 
solution that functions to block irrelevant bands.   
The results obtained from the immunocytochemistry and western blot 
experiments were relatively variable in nature. The images coinciding with the 
immunocytochemistry showed that the PGRMC1 receptor and the PAIRBP1 
protein were detected in the surface cells of the fetal and neonatal mouse ovary 
from 15.5 dpc to PND 5, but not within the oocytes themselves. The 
immunocytochemistry images also showed no detection of PGRMC2 anywhere 
within the ovary during that same timeframe. The results from the western blots 
showed that PGRMC1 was expressed at consistent levels in the mouse ovary from 
15.5 dpc to PND 5, but PAIRBP1 showed increased expression as oocyte 
development proceeds. Similar to the immunocytochemistry results obtained for 
PGRMC2, there didn’t appear to be any expression of PGRMC2 from 15.5 dpc to 
PND 5.  
Given the inconclusive results, future studies will need to be conducted in 
order to learn more about PGRMC1, PGRMC2 and PAIRBP1 and their dynamic 
function in the process of oocyte development. The experiments completed here 
will need to be repeated in order to obtain more conclusive data. Other types of 
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experiments, such as organ cultures, could be extremely beneficial in 
investigating the function of these progesterone signaling components and their 
long-term effect on oocyte development. Organ culture experiments would 
involve growing ovaries in a completely sterile environment for several days in a 
special solution that will block the function of the corresponding receptor/protein 
as the ovaries develop. Once the organ culture is complete, the ovaries can be 
stained using the immunocytochemistry protocol in order to determine how the 
function-blocking mechanism affects the overall number of individual oocytes 
that are present at the end of oocyte development.  
The field of research that is dedicated to exploring the role of progesterone 
in oocyte development and the hormone’s corresponding signaling pathways is 
expanding and will hopefully continue to grow in the coming years. Recent 
research has focused more on how progesterone receptors, such as PGRMC1 and 
PGRMC2, play a role in cancer, which is of crucial importance. However, 
continued research revolving around progesterone signaling receptors and 
proteins could assist in a better understanding of the complex process of oocyte 
development and the potential infertility conditions that could arise if a 
malfunction occurs. 
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Introduction 
 
The act of reproducing is an innate human function that is necessary for 
the survival of our species. The process of reproduction is quite diverse across 
species, but the overall goal is unanimous; to procreate in order to maintain our 
existence. In terms of human reproduction, the process is extremely complex and 
has evolved to signify more than strictly procreation. There are so many minute 
details and functions that must simultaneously work in unison in order to 
successfully conceive a child that it is no surprise that infertility is a prominent 
issue that people are continuing to struggle with.  
Roughly 12% of women in the United States, who are at reproductive age, 
face difficulties with fertility (Chandra et al., 2006). In retrospect, this is a 
significant proportion of women that are experiencing fertility issues, often times 
not knowing exactly what the cause is or how to go about fixing it. A major 
concern to consider is the fact that women produce their complete supply of 
viable eggs long before they even consider reproducing. With no ability to 
produce any more eggs after that crucial point in development, it is impossible to 
realize the reproductive outcome until it is too late (Skinner, 2005). During this 
process of oocyte development, which is complete and irreversible upon birth, a 
woman loses a significant percentage of potential oocytes. Even though this rapid 
decrease in oocyte numbers is observable, it is far from being completely 
understood or explained. If we had a clearer and more concise understanding of 
the various processes involved in oocyte development, specifically focusing on 
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sporadic oocyte loss, then we could potentially gain a better understanding of 
possible infertility triggers and how to better aid individuals being affected by 
difficulties with infertility.  
Although, ideally, we would prefer to learn more about this complex 
process in humans, it is more realistic and feasible to study the process of oocyte 
development in a model organism that is most similar to humans in terms of 
reproductive qualities. In the Pepling Lab we use the species Mus musculus as a 
model organism for research purposes. Being one of the most closely related 
model organisms to humans, mice share a number of commonalities with humans 
in this aspect of development, which makes the results obtained from research 
somewhat transferable across species. The mouse genome is entirely sequenced, 
which makes it a reliable organism to use for research purposes since a great deal 
of background information has already been collected. This fully sequenced 
genome is also relatively easy to manipulate in order to create a variety of 
genetically modified, or transgenic, strains of mice to be used for research. The 
ability to quickly and easily produce transgenic mice is a predominant quality that 
makes the species so marketable for biological research.  
In terms of laboratory use, mice are a relatively easy model organism to 
contain in a laboratory setting. They are small in size and easily maintainable. 
They are not a difficult species to breed and their embryonic development is 
relatively short, lasting 19.5 days on average, with a relatively larger number of 
pups being produced. The short gestation period, coupled with the larger number 
of pups being born in relation to other mammals, provides opportunities to 
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acquire a large amount of data across a short period of time. This turnover rate 
would not be possible using other mammalian model organisms that possess 
relatively the same similarity to humans, but require a longer gestation period and 
give birth to a smaller number of offspring.  
As in human females, female mice begin the reproductive process long 
before birth. Initially, precursor cells, known as primordial germ cells migrate to 
the developing gonad of the fetus at approximately 10.5 days after conception, 
also known as days post coitum (dpc) (Pepling, 2006). Upon arrival at the gonad, 
the primordial germ cells begin to divide via mitosis, forming clusters  
 
Figure 1: A timeline of mouse germ cell development ranging from 11 dpc to 
PND 6. Significant developmental stages are labeled, with the green structures 
representing germ cells and the red structures representing somatic granulosa cells 
(adapted from Pepling, 2006).  
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known as germ cell cysts (Pepling and Spradling, 1998). At this stage, the 
primordial germ cells divide mitotically, where cytokinesis does not go to 
completion and the cells of the cyst remain connected by intercellular bridges 
(Pepling et al., 1999). At this point the cells are known as oogonia. Once the 
process of mitosis is complete, the oogonia begin the process of meiosis at 
roughly 13.5 dpc, as shown in Figure 1, and become oocytes. However, the 
meiotic process is then arrested at the diplotene stage of meiosis I. It was thought 
that the process of meiosis and the consecutive meiotic arrest occur at precisely 
the same time, across all oocytes, but it has been determined that the meiotic 
process often does not occur collectively for all oocytes (Pepling, 2006).  The 
oocytes remain in cysts, surrounded by somatic cells, for several consecutive days 
of development. As shown in Figure 1, at roughly 18 dpc, cyst breakdown is 
triggered and the compacted germ cell cysts begin to separate. This process of 
cyst breakdown signals the maturation of the germ cells into individual oocytes. 
Following the days after birth, also known as post-natal days (PND), cyst 
breakdown progresses. By PND 5, the majority of the germ cells have matured 
and formed individual primordial follicles, containing a single oocyte surrounded 
by a layer of granulosa cells, as shown in Figure 1 (Pepling and Spradling, 2001).  
The timing of cyst breakdown coincides with another fundamental process 
that occurs during oocyte development, germ cell death.  As shown in Figure 1, 
only slightly after the beginning of cyst breakdown is randomized germ cell 
death, known as apoptosis, initiated. In an older scientific model it is thought that 
the ongoing process of cyst breakdown is facilitated by continued apoptosis of 
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Figure 2: Images depicting the difference between a normal follicle (A) versus a 
multiple oocyte follicle (B) in the adult ovary. The green staining signifies STAT 
3 antibody staining the cytoplasm of the oocytes and the red staining signifies 
propidium iodide staining the nuclei of the oocytes, as well as the nuclei of the 
granulosa cells (Pepling, 2006).  
 
cells within the cysts, demonstrating that cell death is essential in order for this 
process to occur and, in turn, the formation of primordial follicles (Pepling and 
Spradling, 2001). However, sometimes cyst breakdown does not go to completion 
and an irregular follicle, known as a multiple oocyte follicle (MOF), forms. 
Multiple oocyte follicles consist of several oocytes enclosed within a single 
follicle, surrounded by a layer of granulosa cells, as depicted in Figure 2. These 
MOFs are thought to contain inviable eggs for future reproduction and, therefore, 
could potentially contribute to causes of infertility.  
 
   
Figure 3: Structures of the hormones discussed, including estrogen (A), estradiol 
(B) and progesterone (C).  
      
A B C 
A B 
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The process of cyst breakdown, coupled with apoptosis, is a critical stage 
in oocyte development that we are consistently attempting to gain a better 
understanding of. Prior research has demonstrated that steroid hormones such as 
estrogen, specifically in the form of estradiol, as shown in Figure 3, possess the 
ability to inhibit cyst breakdown. This inhibition of cyst breakdown leads to a 
decreased number of functional oocyte follicles in the ovary, which could, in turn, 
lead to an increased chance for infertility (Chen et al., 2007; Jefferson et al., 
2006). Additional hormones, such as progesterone, have been shown to block cyst 
breakdown in the neonatal mouse ovary when expressed at high levels, as well. 
Even though the function of estrogen, in the form of estradiol, on cyst breakdown 
in female mice has received vast attention, progesterone is also a hormone that 
produces roughly the same effects (Chen et al., 2007).  Estrogen and progesterone 
individually have the ability to alter the process of cyst breakdown, but these 
hormones are also known to additively block cyst breakdown when their effects 
are combined.   
Progesterone, as shown in Figure 3, is a naturally occurring hormone that 
plays a crucial role in a number of different functions throughout the body. 
Progesterone is known to be involved in hypothalamus and pituitary activity, as 
well as mammary gland and uterine development. The most significant 
application of progesterone for research in the Pepling Lab focuses on the role of 
progesterone in intra-ovarian activity, specifically follicular development. 
Progesterone continues to play a consistent role in future female reproductive 
processes, ranging from menstruation to menopause. This demonstrates how 
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crucial of a contributor progesterone is throughout a woman’s lifetime, starting 
before birth. In order for progesterone to serve these various functions, a number 
of different signaling pathways must be utilized in order to distinguish between 
particular functions in which progesterone is necessary at different points in time.   
 
 
Figure 4: Diagram depicting the potential steps involved in the inhibition of cyst 
breakdown upon the binding of progesterone to either a nuclear receptor or a 
membrane receptor. P represents the progesterone signal and the biological 
function produced in this particular case would be the inhibition of cyst 
breakdown (Dzadyk, unpublished).     
 
The signaling pathways of steroid hormones vary, but, as with any 
signaling pathway, the receptors play a crucial role in the progression of the 
signal, whether it is an estrogen or progesterone signaling pathway. As shown in 
Figure 4, progesterone signaling can occur in a variety of ways through either 
nuclear or membrane receptors that could potentially signal to inhibit cyst 
breakdown in the mouse ovary (Peluso, 2006). Nuclear receptors such as 
progesterone receptor-A (PR-A) and progesterone receptor-B (PR-B) originate 
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from the same gene and are translocated to the nucleus upon binding progesterone 
in the cytoplasm (Pepling, 2012). The translocated receptor/hormone complex 
activates regions of target genes that will elicit the intended progesterone response 
via transcriptional and translational mechanisms (Leonhardt et al., 2003). This 
signaling pathway is thought to take relatively longer than alternative 
progesterone signaling pathways, seeing as transcriptional and translational 
mechanisms proceed over a longer period of time.  
Another known progesterone signaling pathway involves the use of 
cellular membrane receptors, known as progesterone receptor membrane 
components (PGRMCs).  Known cellular membrane receptors that play a role in 
progesterone signaling are PGRMC1 and PGRMC2. Progesterone binds to these 
receptors, a secondary messenger is activated and a signaling cascade proceeds 
until the desired biological function is produced. Not nearly as much is known 
about these cellular membrane receptors as is known about the nuclear receptors, 
which is why they are of particular interest in this research. However, previous 
studies have demonstrated that the term cellular membrane receptor is somewhat 
of a misnomer, because these receptors are not strictly limited to the cellular 
membrane. Even though they were first discovered in the cellular membrane, they 
have since been found to be expressed in the nucleus, as well as a number of other 
intercellular membranes, such as the membranes of endoplasmic reticulum, 
depending on the type of cell they are localizing in (Wendler and Wehling, 2013). 
These observations further intrigue researchers to learn more about PGRMC1 and 
PGRMC2, their origins and applications in mouse oocyte development.   
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Slightly more information is known about PGRMC1 and more current 
research is being conducted in order to learn more about the function of this 
receptor. Although PGRMC1 has been shown to be involved in a number of 
functions outside of the ovary, it does play a significant role in later stages of 
oocyte development, leaving the question of whether or not it affects earlier 
developmental processes, such as cyst breakdown and apoptosis, as well. 
PGRMC1 acts to mediate progesterone activity and these receptors are a prime 
candidate due to the fact that they possess such a strong binding affinity for 
progesterone (Peluso, 2013). PGRMC1 serves as a mediator for the anti-apoptotic 
function that progesterone expression induces, either enhancing the effect and 
reducing the number of germ cells lost or reducing the effect if the receptor is 
inhibited, leading to a spike in apoptotic activity (Peluso et al., 2008). This 
function of PGRMC1 is important since the coupled processes of apoptosis and 
cyst breakdown are both influenced by progesterone, with progesterone having an 
anti-apoptotic effect on the process of germ cell death that coincides with 
inhibited cyst breakdown. Learning more about the use of the PGRMC1 signaling 
pathway for the anti-apoptotic effect of progesterone will only help us gain more 
information regarding progesterone’s synchronous effect on cyst breakdown. 
Unlike other estrogen and progesterone receptors, research studies on 
PGRMC1 have found the receptor to localize to a number of different areas, 
including the nucleus, the cytoplasm and other intracellular membranes in the 
ovary (Lösel et al., 2008). This localization pattern is conserved within mice and 
humans, and, specifically in granulosa cells within the ovary, PGRMC1 is 
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expressed in the plasma membrane, the cytoplasm and sometime the nucleus 
(Peluso, 2006).  Granulosa cells act as protective, nursing cells surrounding the 
individual oocytes, and since progesterone manipulates granulosa cell function via 
the PGRMC1 receptor, it allows for the consequential manipulation of oocyte 
development. Alterations in these PGRMC1-progesterone interactions have been 
shown to have effects on future female reproductive processes, and, in turn, 
fertility capabilities.  
Even less information is known about PGRMC2, with minimal recent 
research having been conducted in order to gain more knowledge about the 
receptor and its functions. The majority of current information available on this 
receptor has been obtained from studies conducted using rats as the model 
organism, and the researched presence of PGRMC2 in humans does not explicate 
that the receptor is strictly present in the female ovary (Cahill, 2007; Chen et al., 
2010). Limited information that is known states that PGRMC2 is quite 
homologous to PGRMC1 (Albrecht et al., 2012). Some research has been 
conducted studying the effects of PGRMC2 on ovarian cancer cells, and its 
potential to act as a tumor suppressor (Albrecht et al., 2012). This potential 
PGRMC2 function differs drastically from PGRMC1 seeing as PGRMC1 is 
thought to be a tumor promoter when studying cancer cells. Even though some 
research has investigated the role of PGRMC2 in cancer cells, little information is 
known regarding the role of PGRMC2 in oocyte development. Previous studies in 
the Pepling Lab, using immunocytochemistry, have demonstrated that the 
progesterone receptor, PGRMC2, is present in the fetal mouse ovary at 15.5 dpc 
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(Dzyadyk and Pepling, unpublished). However, further research looking into the 
expression of PGRMC2 throughout the entirety of mouse oocyte development 
will be discussed later on in the paper.   
There are several other proteins that are thought to interact with either 
PGRMC1 or PGRMC2, or both receptors, and researchers are attempting to gain 
more information about these proteins in order to learn more about the receptors 
that they work together with. The plasminogen activator inhibitor 1 RNA-binding 
protein (PAIRBP1) is thought to interact with PGRMC1 in the PGRMC1-
progesterone signaling pathway.  Since PAIRBP1 does not appear to possess any 
type of transmembrane domain that could allow the protein to function as a 
receptor in a signal transduction pathway, PAIRBP1 binds to and uses PGRMC1 
as a means to affect the progesterone signaling pathway (Peluso, 2006).  
Even though progesterone’s effect on cyst breakdown in mouse germ cell 
development has been discussed, progesterone is also known to have an inhibitory 
effect on the process of apoptosis. Although the signal mechanism of PAIRBP1 is 
unknown, the interaction between PAIRBP1 and PGRMC1 is thought to be 
necessary in order for progesterone to successfully inhibit apoptosis (Peluso et al., 
2013). This anti-apoptotic function has a prominent effect on granulosa cells and 
spontaneously immortalized granulosa cells, specifically in the rat. The fact that 
PGRMC1 is known to be expressed in numerous areas throughout the granulosa 
cell, whereas PAIRBP1 has been found to be expressed only in the plasma 
membrane and cytoplasm of these cells, could be signifying the limitations of 
PAIRBP1 activity as a component of the progesterone-PGRMC1 signal 
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transduction pathway that does not affect the cell at a nuclear level. It is believed 
that there is a particular amino acid sequence in PGRMC1 that is responsible for 
its binding with PAIRBP1, and studies have been conducted using this amino acid 
sequence in order to understand its implications on the PGRMC1-PAIRBP 
interaction and how manipulations of this sequence can affect biological 
processes on a larger scale (Peluso et al., 2013).  
Again, not nearly as much information is known about the potential 
interaction of the PAIRBP1 protein with PGRMC2. However, since PGRMC2 is 
a member of the PGRMC family and shares a number of similarities with 
PGRMC1, it is thought that a similar anti-apoptotic effect is dependent upon an 
interaction between PAIRBP1 and PGRMC2. The crucial amino acid sequence 
found in PGRMC1 is known to be roughly 80% identical in PGRMC2, 
demonstrating that the effects of this sequence could be transferable across either 
member of the PGRMC family (Peluso et al., 2013).    
The goal of this research is to gain a more in depth understanding of 
PGRMC1 and PGRMC2 as individual contributors, as well as the PAIRBP1 
protein, to the intricate processes involved in oocyte development within the 
mouse ovary. If we can acquire more detailed knowledge regarding the 
timeframes in which these membrane receptors and corresponding protein are 
expressed throughout oocyte development and the level of expression at each 
crucial stage, then maybe we could gain a more clear and concise understanding 
of each stage of oocyte development, specifically cyst breakdown and apoptosis, 
which could have such direct effects on future fertility concerns. 
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Materials and Methods 
 
Animals 
      
Research in the Pepling Lab was conducted using the species, Mus 
musculus, as the model organism. The specific transgenic strain of mice that I 
used for my research was the inbred strain, C57BL/6J (B6). Mice were originally 
supplied from companies, such as Jackson Labs, but breeding also took place 
within the laboratory animal resource facility located on campus at Syracuse 
University. All of the mice used for experiments were maintained and cared for in 
the laboratory animal resource facility, as well, with collaborative efforts between 
members of the Pepling Lab and the laboratory animal facility staff.  
Matings between male and female B6 mice were set up every Monday 
afternoon at approximately 2PM, caging 2 females with 1 male per cage. Females 
were then checked for a vaginal plug each morning before 10AM for the 
remainder of the week as a sign of conception. Females that appeared to have a 
vaginal plug were isolated and their plug date was recorded in order to keep track 
of expected birth dates for litters of mice. On the final day of the mating week, 
regardless of whether or not a female mouse had conceived, the females were 
isolated. Pregnant females would then give birth approximately 19.5 days after 
conception, also known as days post coitum (dpc). The day of birth was known as 
post-natal day 1 (PND 1) and every day after the pups’ birth is referenced in terms 
of post-natal days. Occasionally, litters would not necessarily be born on the 
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expected due date, but the age of litters was always determined strictly by plug 
date, not by birth date, when considering ages of litters for research purposes.  
 
Dissection 
 
For my particular project, I obtained ovaries from B6 litters ranging from 
15.5 dpc through PND 5. This required performing fetal dissections and post-natal 
dissections. Fetal dissections required euthanizing the pregnant female by CO2 
asphyxiation using a Euthenex machine in order to dissect the fetal pups. Fetal 
pups were removed from the amniotic sac and separated from the placenta in 
order to dissect them individually. Pups taken at post-natal day ages were simply 
removed from the mother’s cage for dissection and were sacrificed by 
decapitation. A dissecting microscope was used in order to magnify the animals 
that were being dissected and dissections took place in phosphate buffered saline 
(PBS) solution, which served as a solution similar to where the ovaries were 
naturally maintained. Once dissection of the ovaries was complete, ovaries were 
transferred to a solution known as fix, which consists of 200 µL of 16% 
formaldehyde and 400 µL of 1x PBS. The ovaries were placed in fix in order to 
preserve the tissue at the stage at which it was dissected and to prevent the ovaries 
from deteriorating. Ovaries were then incubated in this solution overnight at 4˚C 
on a nutator in a tube labeled with the age at which the ovaries were dissected, the 
dissection date and the number of ovaries collected. The stored ovaries could then 
be used for future experiments, such as whole mount antibody staining.  
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Whole Mount Antibody Staining   
            
After being incubated overnight in the solution of fix, a detailed protocol 
was followed to perform an antibody staining procedure using indirect 
immunofluorescence. Typically, I focused on collecting data from antibody 
stainings performed at 15.5 dpc, since the various antibodies that I use are thought 
to be highly expressed at that stage in mouse oocyte development. Therefore, the 
specific protocol that I followed was designed specifically for antibody staining of 
fetal mouse ovaries. Following incubation in fix, ovaries were quickly washed 
two times in 1 mL of PT, which is a solution consisting of 1x PBS and 0.1% of 
Triton X-100. Then, they were incubated in 1mL of PT for approximately 30 
minutes at room temperature on a nutator. Next, the ovaries were incubated in 1 
mL of PT + 5% BSA. The incubation time in PT + 5% BSA could be modified in 
several different ways. The ovaries could either be incubated in the solution for 1 
hour at room temperature on a nutator or the ovaries could be incubated in the 
solution overnight on a nutator at 4˚C. Either method yielded identical results and 
did not affect the end product.  
After incubation in the PT + 5% BSA solution, the ovaries were incubated 
with the primary antibody being used in the staining procedure. Different 
antibodies have certain dilutions at which they will optimally label the tissue in 
immunofluorescence procedures, so I used several different primary antibody 
dilutions throughout the various antibody stainings that I performed. As 
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Table 1: Primary antibodies used in whole mount antibody staining 
procedure 
 
Primary 
antibody  
Company Lot Number Antibody 
function 
Dilution 
amount 
used in 500 
µL of 
PT+5% 
BSA 
PGRMC1 Santa Cruz 
Biotechnology 
C1510 labels 
PGRMC1 
receptor 
5 µL 
PGRMC1  Sigma Aldrich  C41005 labels 
PGRMC1 
receptor 
5 µL 
PGRMC2 Santa Cruz 
Biotechnology 
L0312 labels 
PGRMC2 
receptor 
5 µL 
PGRMC2 Sigma Aldrich R38704 labels 
PGRMC2 
receptor 
5 µL 
PAIRBP1 Abcam GR151078-1 labels 
PAIRBP1 
protein 
5 µL 
STAT 3 Santa Cruz 
Biotechnology 
I0613 oocyte 
marker 
1 µL 
 
shown in Table 1, when staining for the expression of STAT 3, a dilution factor of 
1:500 was used; whereas staining for the expression of PGRMC1, PGRMC2 or 
PAIRBP1 required a larger concentration of antibody with a dilution factor of 
1:100 in order to adequately express the proteins of interest. However, the nature 
of the solution in which the primary antibody was diluted, and the exact volume 
of that solution used, was consistently 500 µL of PT + 5% BSA.  After adding the 
PT + 5% BSA and the appropriate primary antibody, the ovaries were incubated 
overnight on a nutator at 4˚C. At this time, the solution containing the secondary 
antibody was made in order to allow the secondary antibody to appropriately pre-
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absorb. A very small pinch of embryo powder, 500 µL of PT + 5% BSA and 2.5 
µL of the corresponding secondary antibody are all added together in a tube and 
incubated overnight on a nutator at 4˚C alongside the ovaries being incubated in 
the primary antibody. The different secondary antibodies used depending on the 
species in which the primary antibody originated are listed in Table 2. The 
secondary antibody solution was maintained in foil the entire time, since it is 
fluorescent and light sensitive, which are characteristics that make it possible to 
visualize the stained ovaries at the end of the procedure.  
 
Table 2: Secondary antibodies used in whole mount antibody staining 
procedure 
 
Secondary 
antibody 
Company Wavelength 
(nm) 
Antibody 
function 
Dilution 
used in 
500µL 
PT+5% 
BSA (µL) 
donkey anti-
goat 
Molecular 
Probes 
488 nm indirectly 
labels 
PGRMC2  
2.5 µL 
donkey anti-
mouse 
Molecular 
Probes 
488 nm indirectly 
labels 
PAIRBP1 
2.5 µL 
donkey anti-
rabbit 
Molecular 
Probes 
488 nm indirectly 
labels 
PGRMC1and 
PGRMC2  
2.5 µL 
goat anti-
mouse 
Molecular 
Probes 
488 nm indirectly 
labels 
PAIRBP1 
2.5 µL 
goat anti-rabbit Molecular 
Probes 
488 nm Indirectly 
labels 
PGRMC1 and 
Stat 3 
2.5 µL 
rabbit anti-goat Molecular 
Probes 
488 nm indirectly 
labels 
PGRMC2 
2.5 µL 
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The following day, the ovaries were washed in 1 mL of PT + 1% BSA for 
no less than 30 minutes on a nutator at room temperature. Then, the ovaries were 
incubated in RNase A solution, containing 10 µL of 10 mg/mL RNase A and 1 
mL of PT + 1% BSA, for exactly 30 minutes on a nutator at room temperature. 
Next, the ovaries were incubated in a solution containing 10 µL of 0.5 mg/mL 
propidium iodide  and 1 mL of PT + 1% BSA for exactly 20 minutes on a nutator 
at room temperature, in complete darkness in order to preserve the effect of the 
propidium iodide. From this point on, all the steps in the staining process were 
completed in foil-wrapped tubes in order to preserve the fluorescent staining 
reagents. After incubation in propidium iodide, the ovaries were washed in 1 mL 
of PT + 1% BSA for approximately 30 minutes on a nutator at room temperature. 
The ovaries were then incubated in a solution containing 2.5 µL of the pre-
absorbed secondary antibody solution with 500 µL of PT + 5% BSA, as shown in 
Table 2, for either 2-4 hours on a nutator at room temperature or overnight on a 
nutator at 4˚C.  
On the final day, the ovaries were washed three separate times in 1 mL of 
PT + 1% BSA, for 30 minutes each time, on a nutator at room temperature. The 
ovaries were then washed quickly in 1 mL of 1x PBS before mounting the ovaries 
on a new slide. In order to transfer the ovaries to the slide, roughly 700 µL of 1x 
PBS was removed from the tube containing the ovaries after the wash was 
complete. A new pipette tip was then cut at an angle to create a larger opening in 
which the ovaries would freely be able to be pipetted out on the tube, into the tip 
and back onto the slide. Once the ovaries were transferred to the slide and any 
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excess 1x PBS was removed from the slide, 2 drops of VectaShield were added to 
the slide. A coverslip was carefully placed on the top of the slide and the ovaries 
sat in the VectaShield in the dark for approximately 15 minutes, because the 
VectaShield served to further preserve the fluorescent character of both the 
propidium iodide and the secondary antibody for visualization later on. Nail 
polish was then spread around the exterior of the coverslip in order to ensure that 
the coverslip was secure and the slide was labeled with sex of gonads, the age at 
which the gonads were dissected, the primary and secondary antibodies used for 
the staining, the current date and my personal initials. After the nail polish had 
completely dried, the completed slide was placed in a folder to prevent exposure 
to light and the folder was stored in the freezer at -20˚C.    
 
Confocal Microscopy 
 
Confocal microscopy is an effective method used to visualize the staining 
patterns on a specimen. The microscope uses point illumination to pinpoint a 
discrete region of the specimen in which the fluorescent reagent that the specimen 
was stained with can be made visible. Ovaries that were stained using the whole 
mount antibody staining protocol were visualized using the Zeiss LSM 710 
confocal microscope located in the imaging room at the Life Sciences Complex at 
Syracuse University. When observing the slides under the microscope, the ovaries 
were first looked at using a 10x objective lens, in order to locate and focus on 
individual ovaries on the slides. Once an ovary was clearly visible under the 10x 
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lens, a drop of oil was added and the magnification was increased to a 63x 
objective in order to observe various stages of oocyte development occurring 
within the individual ovaries. The confocal microscope was used to analyze the 
appropriately labeled proteins that coincided with the antibodies that were used to 
stain for their expression during the antibody staining procedure. In this case, in 
order to visualize the appropriate fluorescent wavelength, the confocal reflector 
used was always alexa-fluoro-488, which would allow the fluorescing secondary 
antibody reagent to be made visible under the confocal microscope. Images of the 
stained ovaries would be taken on a computer linked to the Zeiss confocal 
microscope, using Zen 2010 software, and could then be transferred to a disc for 
future reference outside of the imaging room. 
 
Western Blotting 
 
Western blotting is a technique that can be used to test for the presence of 
certain proteins at various stages in development. Western blot analysis also 
provides subsequent information about the magnitude of protein expression across 
developmental stages. In order to determine protein expression throughout oocyte 
development, I dissected ovaries at several days of fetal and neonatal 
development, specifically 15.5, 17.5 dpc and PND 1, 3 and 5. The dissection 
protocol was slightly altered when preparing ovaries for western blotting. Ovaries 
were still dissected in 1x PBS, but were then transferred to an eppendorf tube 
containing approximately 500 µL of ice-cold 1x PBS. After all of the ovaries 
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were dissected and transferred to the tube, the 1x PBS was removed and a 
proportionate supply of 1x Sample Buffer plus protease inhibitors was added. 1x 
Sample Buffer consists of 500 µL of 2x Sample Buffer, 100 µL of 10x protease 
inhibitors and 400 µL of distilled water. For each ovary dissected, 10 µL of 1x 
Sample Buffer was added, being sure that only 50 µL of 1x Sample Buffer was 
added at a time. Once the first 50 µL of Buffer was added, the ovaries were 
homogenized using a pestle and then any additional required Buffer was added to 
finish the process. From the moment the ovaries were dissected until the moment 
that they were homogenized, it was critical that the ovaries were kept on ice. Once 
homogenization was complete, the tube containing the ovary extracts was labeled 
with the age of the ovaries, the date of the dissections, the number of ovaries 
homogenized and my personal initials. The homogenized ovary extracts were then 
stored in the freezer at -20˚C, until they were needed to run a western blot.   
Once enough ovary extracts were collected from a variety of fetal and 
neonatal ages, the electrophoresis step of the western blot was initiated. In order 
to prepare the samples, 20 µL of each extract and 2 µL of 2-mercaptoethanol were 
added to an eppendorf tube. The samples were then boiled for 3 minutes and 
centrifuged for 1 minute at 6000 rpm, being returned to ice after each step. The 
gel apparatus was assembled, the BioRad Mini Protein Gel was inserted into the 
gel holder and the appropriate amount of 1x Running Buffer, consisting of 100 
mL of 10x SDS Glycine Running Buffer diluted in 900 mL of milli-Q water, was 
added. The wells of the gel were cleaned out to avoid bubbling, and then the 
samples were loaded into the individual wells. 10 µL of Precision Plus Standard 
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Protein marker were loaded into the first well to serve as a reference ladder. 
Positive control lysates were also used as a means of regulating the efficiency of 
the protocol being used and to ensure that the antibodies being used were 
functioning properly. A Hep G2 cell lysate was used as a positive control for the 
PGRMC1 antibody used and a HeLa whole cell lysate was used as a positive 
control for the PGRMC2 and the PAIRBP1 antibodies used. 20 µL of each 
positive control lysate were loaded into the appropriate wells on the gel. 20 µL of 
the boiled and spun ovary samples were then loaded into the wells in order of 
increasing age. The gel was then run at approximately 100 volts for 1 hour.  
Once electrophoresis was complete, the resulting bands present on the gel 
were transferred to a polyvinylidene fluoride transfer membrane for manipulation 
with the desired antibodies. Before the transfer procedure occurs, the transfer 
membrane was soaked in methanol for 1 minute then milli-Q water for 5 minutes. 
The membrane, BioRad gel, 2 pieces of filter paper and 2 filter pads were then 
individually soaked in transfer buffer, consisting of 3.0 grams of Tris base, 14.4 
grams of glycine and 200 mL of methanol diluted in milli-Q water to a total 
volume of 1 liter, for 5 minutes. After being soaked in transfer buffer, a transfer 
sandwich was assembled within a transfer cassette, laying one fiber pad, one piece 
of filter paper, the gel, the transfer membrane, the second piece of filter paper and 
the second filter pad down on the cassette. The closed cassette was then placed in 
the transfer apparatus, an ice-cube was added, a small stir bar was placed in the 
bottom and the apparatus was filled with transfer buffer. The entire apparatus was 
relocated to the 4˚C refrigerator and the transfer took place at 4˚C at 100 volts for 
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1 hour. Once the transfer was complete, the membrane was placed in blocking 
buffer on a shaker at room temperature for 30 minutes to block any future non-
specific binding of proteins once the detection antibodies were added. After 30 
minutes, the blocking buffer was changed and the membrane was incubated in 
fresh blocking buffer overnight on the nutator at 4˚C. The blocking buffer used 
depended upon the particular detection antibody. When working with a PGRMC1 
antibody, a PGRMC2 antibody made in rabbit, or a PAIRBP1 antibody, standard 
blocking buffer was used throughout the protocol, which consisted of 100 mL of 
10x PBS, 50 g of non-fat dry milk and 0.5 mL Tween 20 diluted in milli-Q water 
to a total volume of 1 liter. When working with a PGRMC2 antibody made in 
goat, the ingredients of the blocking buffer had to be altered due to the origin of 
the antibody. The PGRMC2 antibody used was produced in goat and the milk 
used in standard blocking buffer is known to cross-react with antibodies made in 
goat, leading to non-specific protein binding. The 5% non-fat dry milk in blocking 
buffer was substituted with 50 µL of goat serum (Molecular Probes, Lot # 
1114869A) in order to avoid error.  
The following day, a primary antibody and its corresponding secondary 
antibody were applied to the membrane in order to test for the presence of a 
protein of interest. The membrane was first incubated in a solution of the primary 
antibody diluted in blocking buffer. The antibody dilution is typically 1:1000, but 
varies depending on the particular antibody. As shown in Table 3, the antibodies 
used were often diluted much less than normal. The membrane incubation in 
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Table 3: Primary antibodies / lysates used for western blotting 
 
Primary 
antibody/lysate 
Company Lot 
Number 
Antibody/lysate 
function 
Dilution in 
blocking 
buffer 
(BB) 
GAPDH Santa Cruz 
Biotechnology 
E0912 loading control 
antibody 
1:5000 (1 
µL:5mL) 
HeLa whole 
cell lysate 
Santa Cruz 
Biotechnology 
I0612 positive control 
lysate for several 
antibodies 
N/A 
Hep G2 cell 
lysate 
Santa Cruz 
Biotechnology 
E1012 positive control 
lysate for an 
antibody  
N/A 
PAIRBP1 Abcam GR151078-
1 
detect expression 
of PAIRBP1 
protein 
1:100 (30 
µL: 3 mL  
PGRMC1 Sigma Aldrich C41005 detect expression 
of PGRMC1 
receptor 
1:500 (6 
µL: 3 mL) 
PGRMC2  Santa Cruz L0312 detect expression 
of PGRMC2 
receptor 
1:1000 (3 
µL: 3 mL) 
PGRMC2 Sigma Aldrich R38704 detect expression 
of PGRMC2 
receptor 
1:100 (30 
µL: 3 mL) 
     
primary antibody solution varied in time and temperature depending on the nature 
of the primary antibody. When the membrane was incubated using PGRMC1 as 
the primary antibody, incubation occurred for 1 hour on a nutator at room 
temperature. When the membrane was incubated using PGRMC2 or PAIRBP1 as 
the primary antibody, the membrane was incubated in solution overnight on a 
nutator at 4˚C. The membrane was then washed in blocking buffer 3 separate 
times, for 10 minutes each, on a shaker at room temperature.  
 
 
 
 
 
 32
Table 4: Secondary HRP-conjugated antibodies used for western blotting 
  
Secondary 
antibody 
Company Lot 
Number 
Antibody function Dilution in 
BB 
goat anti-
mouse 
Pierce Immuno 
Pure Antibodies 
FI814529 Indirectly detects 
expression of 
PAIRBP1 
1:10,000  
(1 µL:10 
mL) 
goat anti-
rabbit 
Thermo 
Scientific Pierce 
Antibodies 
NL181270 indirectly detects 
expression of 
PGRMC1 
1:10,000  
(1 µL:10 
mL) 
rabbit anti-
goat 
Thermo 
Scientific Pierce 
Antibodies 
OE1711053 indirectly detects 
expression of 
PGRMC2 
1:10,000  
(1 µL:10 
mL) 
 
rabbit anti-
mouse 
Pierce Immuno 
Pure 
Antibodies 
BC631905 indirectly detects 
expression of 
GAPDH and 
PAIRBP1 
1:10,000 
(1µL:10 
mL) 
 
Next, the membrane was incubated in a solution of the secondary 
Horseradish Peroxidase (HRP) antibody diluted in blocking buffer. As shown in 
Table 4, the antibody dilution used for every secondary antibody was 1:10,000, so 
1 µL of secondary antibody was diluted in 10 mL of blocking buffer. The origin 
of the secondary antibody depended on the origin of the primary antibody being 
used, because in order to bind to the primary antibody, it was essential that the 
secondary antibody recognized the primary antibody as an antigen. The 
incubation in the secondary antibody dilution took place on a nutator, at room 
temperature, for 1 hour. Then, the membrane was washed in blocking buffer 2 
additional times, for 10 minutes each, on a shaker at room temperature. The 
membrane was then washed once in wash buffer, consisting of 50 µL of Tween 
diluted in 1 L of 1x PBS, for 10 minutes on a shaker at room temperature. The 
membrane was then quickly rinsed in 1x PBS and incubated in 5 mL of a 
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detection buffer-enhancer solution for 5 minutes on a shaker at room temperature. 
The ratio of detection buffer to enhancer was 1:1, so 2.5 mL of each liquid was 
used in the solution. The membrane was then thoroughly rinsed in milli-Q water, 
wrapped in a clear plastic cover and placed in an autoradiography cassette. The 
membrane was then imaged using a BioRad Molecular Imaging ChemiDoc XRS+ 
Imaging System specialized for western blot detection. Protein bands of interest 
and the intensity of protein expression were detected across different stages of 
mouse development based on the size, shade and location of the bands. Images 
were captured on a program connected to the imaging system and were stored for 
future reference. Once imaging was complete, the membrane was rinsed in 1x 
PBS and blocked in blocking buffer for 30 minutes on a shaker at room 
temperature. Then, the blocking buffer was changed and the membrane was 
incubated in blocking buffer overnight at 4˚C. 
The following day, the detection protocol was repeated, except different 
antibodies were substituted as the primary and secondary antibodies. The 
membrane was reprobed using the loading control protein, glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). GAPDH was used as the primary antibody; 
diluted 1:5000 in blocking buffer. The secondary antibody used was an anti-
mouse HRP antibody, since GAPDH is made in mouse, and was diluted 1:10,000 
in blocking buffer. The reprobing procedure was used to ensure that equal 
amounts of sample were loaded into each well to confirm that resulting 
differences in signal strength were not simply due to over-loading or under-
loading of a well. GAPDH is an efficient loading control protein to use because it 
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is stable across various conditions and typically possesses dependable signal 
strength.  
 
Results 
 
PGRMC1 appears to be expressed in the surface epithelium of the fetal and 
neonatal mouse ovary 
 
The technique of immunocytochemistry was performed to determine if PGRMC1 
was expressed in the fetal mouse ovary at 15.5 dpc and 17.5 dpc and in the 
neonatal mouse ovary at PND 1, 3 and 5.  
The expression of PGRMC1 appears to be limited to the epithelium of the 
fetal and neonatal mouse ovaries, as shown in Figure 5A, C and E. The staining of 
the epithelial cells with the PGRMC1 antibody is relatively strong and appears to 
localize to the cytoplasm, as well as the nuclei of these cells. The rate at which the 
antibody detection diffuses as you progress towards the ovary interior is 
inconsistent and varies from one ovary to another. PGRMC1 was not detected in 
the ovary interiors of these 3 stages, as shown in Figure 5B, D and F.  
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Figure 5: Confocal images of fetal and neonatal mouse ovary sections 
demonstrating expression of PGRMC1 via the PGRMC1 antibody staining 
(green) at the epithelial layer of the ovary. The propidium iodide (red) is staining 
the nuclei of the oocytes, surrounding pre-granulosa and epithelial cells. Images 
of the epithelial cells at 15.5 dpc (A), PND 1 (C) and PND 5 (E) are shown in 
comparison to images of the ovary interior at 15.5 dpc (B), PND 1 (D) and PND 5 
(F).  
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  PND 1  
15.5 dpc  
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PGRMC2 does not appear to be expressed at all throughout fetal and 
neonatal mouse ovary development  
 
The technique of immunocytochemistry was performed to determine if 
PGRMC2 was expressed in the fetal mouse ovary at 15.5 dpc and 17.5 dpc and 
the neonatal mouse ovary at PND 1, 3 and 5.  
 
   
Figure 6: Confocal images of fetal and neonatal mouse ovaries showing no 
expression of PGRMC2 via the PGRMC2 antibody (green). The propidium iodide 
(red) is staining the nuclei of the oocytes and the somatic, or granulosa, cells. 
Ovaries at 15.5 dpc (A), PND 1 (B) and PND 5 (C) only show appropriate 
staining of nuclei within various ovary components.      
 
There does not appear to be any significant expression of PGRMC 2 in the 
mouse ovary at these stages of fetal and neonatal mouse development, as shown 
in Figure 6. There was no expression in the cytoplasm or nuclei of the oocytes or 
the surrounding somatic cells at 15.5 dpc or PND 5. In several ovaries at PND 1, 
the ovaries appear to have weak background staining with no specific localization 
pattern; therefore expression of PGRMC2 in the neonatal mouse ovary is not 
significant at PND 1 either.  
 
A B C 
15.5 dpc PND 1 PND 5 
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PAIRBP1 appears to be expressed in the epithelium of the fetal and neonatal 
mouse ovary 
 
The technique of immunocytochemistry was performed to determine if 
PAIRBP1 was expressed in the fetal mouse ovary at 15.5 dpc and 17.5 dpc and 
the neonatal mouse ovary at PND 1, 3 and 5.  
 
    
   
Figure 7: Confocal images of fetal and neonatal mouse ovary sections 
demonstrating expression of PAIRBP1 via the PAIRBP1 antibody staining 
(green) at the epithelial layer of the neonatal ovary. The propidium iodide (red) is 
staining the nuclei of the oocytes, surrounding pre-granulosa and epithelial cells. 
An image of the ovary at 15.5 dpc (A) is shown. Images of the epithelial cells in 
the neonatal ovary at PND 1 (B) and PND 5 (D) are shown in comparison to 
images of the ovary interior at PND 1 (C) and PND 5 (E). 
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The expression of PAIRBP1 appears to be limited to the epithelium of the 
fetal and neonatal mouse ovaries, as shown in Figure 7. The staining of the 
epithelial cells with the PAIRBP1 antibody is relatively strong and appears to 
localize to the cytoplasm, as well as the nuclei of these cells. The rate at which the 
antibody expression diffuses as you progress towards the ovary interior is 
inconsistent and varies from one ovary to another. PAIRBP1 was not detected in 
the ovary interiors of these 3 stages, as seen in Figure 7. This correlation between 
PAIRBP1 expression and PGRMC1 expression could potentially support the 
hypothesis that PGRMC1 and PAIRBP1 interact in order for the PGRMC1-
progesterone signaling pathway to proceed normally.  
 
PGRMC1 appears to be present throughout fetal and neonatal mouse 
development  
 
The western blotting procedure was performed to confirm that PGRMC1 
is present in the fetal and neonatal mouse ovary and to determine if the levels of 
this membrane receptor change throughout the process of germ line development. 
The expected size of PGRMC1 is 28 kilo Daltons (kD). Ovary extracts at 15.5 
dpc, 17.5 dpc, PND 1, PND 3 and PND 5 were tested using western blot.  
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Figure 8: Image taken from the BioRad Molecular Imaging ChemiDoc XRS+ 
Imaging System showing the PGRMC1 western blot results. The prominently 
detected protein is PGRMC1. Lane 1 consists of the Precision Plus Standard 
Protein marker used as a reference to determine band size. The arrow shows a 25 
kD size marker. Lane 2 consists of the HepG2 whole cell lysate positive control. 
Lane 3 consists of ovary extracts at 15.5 dpc. Lane 4 consists of ovary extracts at 
17.5 dpc. Lane 5 consists of ovary extracts at PND 1. Lane 6 consists of ovary 
extracts at PND 3. Lane 7 consists of ovary extracts at PND 5.  
 
The western blot membrane detection demonstrates that PGRMC1 is 
present in the fetal and neonatal mouse ovary from 15.5 dpc to PND 5, as seen in 
Figure 8. The protein detected appears to be of the appropriate size expected for 
PGRMC1. The protein appears to be slightly larger than the 25 kD reference 
protein size marker, while still being significantly smaller than the 37 kD 
reference protein. The HepG2 whole cell lysate that was used as a positive control 
appeared to have protein detected at the same size as the PGRMC1 protein (28 
kD), which is to be expected considering that the positive control lysate sample 
contains PGRMC1. An additional protein in the HepG2 whole cell lysate was also 
detected at approximately 20 kD. The darkness, or intensity, of the protein from 
15.5 dpc to PND 5 appears to be consistent. This demonstrates that the level of 
PGRMC1 in the mouse ovary across germ line development is relatively stable 
and does not fluctuate significantly. An additional protein was detected at each of 
the ages, located slightly above the 100 kD reference size marker. It is not 
 
25 kD 
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included in Figure 8, because it is not the primary protein signifying the presence 
of PGRMC1 in the fetal and neonatal mouse ovary.  
The western blotting detection procedure was repeated using the loading 
control protein, GAPDH. The same membrane was re-probed using this antibody 
to determine if an equal amount of sample was loaded into each of the wells in 
order to ensure that any change in the protein signal intensity was inherently due 
to a change in expression of the PGRMC1 receptor at that stage of development. 
The expected size of GAPDH is 42 kD, and the same ovary extract ages in Figure 
8 were used here.  
 
                        1            2           3             4             5            6               7 
 
   Figure 9: Image taken from the BioRad Molecular Imaging ChemiDoc XRS+ 
Imaging System showing the GAPDH reprobing results for PGRMC1. The 
prominently detected protein is GAPDH. Lane 1 consists of the Precision Plus 
Standard Protein marker used as a reference to determine protein size. The arrow 
shows a 37 kD size marker. Lane 2 consists of the HepG2 whole cell lysate. Lane 
3 consists of ovary extracts at 15.5 dpc. Lane 4 consists of ovary extracts at 17.5 
dpc. Lane 5 consists of ovary extracts at PND 1. Lane 6 consists of ovary extracts 
at PND 3. Lane 7 consists of ovary extracts at PND 5. 
 
The results from the western blot membrane re-probing procedure, as 
shown in Figure 9, demonstrating that the results from the PGRMC1 detection are 
relatively accurate. The protein detected appears to be of the appropriate size for 
GAPDH. The protein appears to be located slightly above the 37 kD reference 
band, while still being a moderate distance from the 50 kD reference band, which 
demonstrates that it was detected at the expected location on the membrane. An 
37 kD 
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additional protein was detected at approximately 37 kD; the size was difficult to 
determine given the non-linear shape that progressed across the lanes on the 
membrane. The darkness, or intensity, of the bands appears to change slightly 
across the 5 developmental ages. The band detected at 17.5 dpc appears to be 
slightly lighter than the other bands detected, especially in comparison to the 
bands detected at PND 1 and PND 3. The slight fluctuation in protein signal 
intensity of GAPDH could demonstrate that some volumes of sample loaded were 
slightly less than or slightly more than the instructed 20 µL. Given the slight 
fluctuation in the intensity of the GAPDH protein signal, the PGRMC1 levels 
shown in Figure 8 might require re-evaluation. Faint protein signals were also 
detected at approximately 28 kD and 100 kD, but are not shown above. These 
proteins are not shown in Figure 9, because they are remnants from the PGRMC1 
detection.  
 
PGRMC2 does not appear to be present throughout fetal and neonatal 
mouse development  
 
The western blotting procedure was performed to confirm that PGRMC2 
is not present in the fetal and neonatal mouse ovary and to determine if the levels 
of this membrane receptor change throughout the process of germ line 
development. The expected size of PGRMC2 is 24 kD. Ovary extracts at 15.5 
dpc, 17.5 dpc, PND 1, PND 3 and PND 5 were tested using western blot. 
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Figure 10: Image taken from the BioRad Molecular Imaging ChemiDoc XRS+ 
Imaging System showing the PGRMC2 western blot results. There were no 
prominently detected proteins for PGRMC2. Lane 1 consists of the Precision Plus 
Standard Protein size marker. The arrow shows a 25 kD size marker. Lane 2 
consists of the HeLa whole cell lysate. Lane 3 consists of ovary extracts at 15.5 
dpc. Lane 4 consists of ovary extracts at 17.5 dpc. Lane 5 consists of ovary 
extracts at PND 1. Lane 6 consists of ovary extracts at PND 3. Lane 7 consists of 
ovary extracts at PND 5.  
 
The western blot experiment did not detect PGRMC2 in the fetal and 
neonatal mouse ovary extracts, as shown in Figure 10. If PGRMC2 were 
expressed in the fetal and neonatal mouse ovary, a protein of approximately 24 
kD would be expected to be detected in the blot. However, there were no proteins 
detected at the appropriate location expected for PGRMC2. A protein of the 
expected size for PGRMC2 was detected in the HeLa whole cell lysate that was 
used as a positive control. This demonstrates that it was possible for PGRMC2 to 
be detected in at least one sample on the blot. An additional protein was detected 
at approximately 15 kD, as well as an un-identifiable spot slightly below the 100 
kD reference band. Since no protein signals were detected upon imaging the 
membrane, the darkness, or intensity, of PGRMC2 was unable to be determined. 
The western blotting detection procedure was repeated using the loading 
control protein, GAPDH. Typically, this procedure would be used to determine if 
25 kD 
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an equal amount of sample was loaded into each of the wells in order to ensure 
that any change in protein signal intensity was inherently due to a change in 
expression of the PGRMC2 receptor at that stage of development. In this case, the 
membrane was re-probed in order to determine if the original lack of PGRMC2 
expression was due to an error in how the PGRMC2 western blot was conducted, 
or if there was an error with the antibody itself. The expected size of GAPDH is 
42 kD, and the same ovary extract ages in Figure 10 were used here. 
 
            1        2          3          4          5          6           7 
 
Figure 11: Image taken from the BioRad Molecular Imaging ChemiDoc XRS+ 
Imaging System showing the GAPDH reprobing results for PGRMC2. The 
prominently detected protein is GAPDH. Lane 1 consists of the Precision Plus 
Standard Protein size marker. The arrow shows a 37 kD size marker. Lane 2 
consists of the HeLa whole cell lysate. Lane 3 consists of ovary extracts at 15.5 
dpc. Lane 4 consists of ovary extracts at 17.5 dpc. Lane 5 consists of ovary 
extracts at PND 1. Lane 6 consists of ovary extracts at PND 3. Lane 7 consists of 
ovary extracts at PND 5. 
 
The results from the western blot re-probing procedure demonstrated that 
GAPDH was detected from 15.5 dpc to PND 5, as shown in Figure 11. As shown 
by the 37 kD reference protein, the protein signal detected appears to be at the 
appropriate size for GAPDH, only having a slightly different mobility than 
expected. The consistent darkness of the detected protein signal demonstrates that 
an equal amount of sample was loaded into each of the wells upon the original 
37 kD 
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running of the gel; therefore the lack of PGRMC2 detection in Figure 10 was not 
a result of a severely decreased amount of ovary extract present during gel 
electrophoresis. The proteins in Lane 2 of Figure 11, representing the HeLa whole 
cell lysate positive control, appear to be slightly smeared, which might indicate 
that too much of the positive control was used. Definitive protein signals were 
detected from 15.5 dpc to PND 5, demonstrating that the lack of PGRMC2 
expression in Figure 10 is most likely not a result of an error in the western blot 
procedure. These results help narrow down the possible reasons as to why 
PGRMC2 was consistently not detected at all in the mouse ovary throughout fetal 
and neonatal development across a number of western blot experiments.   
 
PAIRBP1 expression appears to increase across fetal and neonatal mouse 
development 
 
The western blotting procedure was performed to confirm that PAIRBP1 
is present in the fetal and neonatal mouse ovary and to determine if the levels of 
this protein change throughout the process of germ line development. The 
expected size of PAIRBP1 is 45 kD. Ovary extracts at 15.5 dpc, 17.5 dpc, PND 1, 
PND 3 and PND 5 were tested using western blot.  
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Figure 12: Image taken from the BioRad Molecular Imaging ChemiDoc XRS+ 
Imaging System showing the PAIRBP1 western blot results. The prominently 
detected protein is PAIRBP1. Lane 1 consists of the Precision Plus Standard 
Protein size marker. The arrow shows a 50 kD size marker. Lane 2 consists of the 
HeLa whole cell lysate. Lane 3 consists of ovary extracts at 15.5 dpc. Lane 4 
consists of ovary extracts at 17.5 dpc. Lane 5 consists of ovary extracts at PND 1. 
Lane 6 consists of ovary extracts at PND 3. Lane 7 consists of ovary extracts at 
PND 5. 
 
The western blot membrane detection demonstrates that PAIRBP1 is 
present in the fetal and neonatal mouse ovary at various levels across germ line 
development, as shown in Figure 12. The protein detected appears to be located at 
approximately the appropriate location correlating with the expected size of 
PAIRBP1. The protein appears to be in line with the 50 kD reference band, which 
is slightly above the expected 45 kD PAIRBP1 size. However, the expected size 
for any given protein is simply an estimate that can fluctuate based on a number 
of different occurrences during the western blot procedure. The PAIRBP1 protein 
detected only slightly deviated from the estimate; therefore these results maintain 
their validity. The HeLa whole cell lysate that was used a positive control did not 
appear to express PAIRBP1 upon treatment with the PAIRBP1 antibody, which 
was unexpected. The darkness, or intensity, of each protein signal from 15.5 dpc 
to PND 5 appears to increase as development progresses. According to the protein 
signal intensities, the expression of PAIRBP1 in the mouse ovary steadily 
increases as germ line development proceeds.  
50 kD 
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The western blotting detection procedure was repeated using the loading 
control protein, GAPDH. The same membrane was re-probed using this antibody 
to determine if an equal amount of sample was loaded into each of the wells in 
order to ensure that any change in protein signal intensity was inherently due to a 
change in expression of the PAIRBP1 receptor at that stage of development. The 
expected size of GAPDH is 42 kD, and the same ovary extract ages in Figure 12 
were used here. 
 
      1           2             3               4               5            6              7 
 
 
Figure 13: Image taken from the BioRad Molecular Imaging ChemiDoc XRS+ 
Imaging System showing the GAPDH reprobing results for PAIRBP1. The 
prominently detected protein is GAPDH. Lane 1 consists of the Precision Plus 
Standard Protein marker. The arrow shows a 37 kD size marker. Lane 2 consists 
of the HeLa whole cell lysate. Lane 3 consists of ovary extracts at 15.5 dpc. Lane 
4 consists of ovary extracts at 17.5 dpc. Lane 5 consists of ovary extracts at PND 
1. Lane 6 consists of ovary extracts at PND 3. Lane 7 consists of ovary extracts at 
PND 5. 
 
The results from the western blot re-probing procedure demonstrated that 
GAPDH was detected from 15.5 dpc to PND 5, as seen in Figure 13. As shown by 
the 37 kD reference size marker, GAPDH is detected at the appropriate size, 
showing only a slightly different mobility on the membrane than expected in 
comparison to the protein size marker. Figure 13 also demonstrates that the results 
from the PAIRBP1 detection were relatively accurate. It appears as though a 
relatively consistent amount of sample was loaded into each of the wells based on 
the similar protein signal intensities seen from 15.5 dpc to PND 5. The HeLa 
37 kD 
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whole cell lysate in Lane 2 of Figure 13 appears to be completely bleached out 
upon detection, which means that an excess amount of positive control lysate 
could have been used, causing the GAPDH protein signal to be overexpressed to 
such an extreme. The results of the PAIRBP1 re-probing demonstrate that the 
PAIRBP1 expression pattern shown in Figure 12 is relevant and could be due to 
the intrinsic variation in expression of the protein across fetal and neonatal mouse 
development. The results in Figure 13 ensure that the expression of PAIRBP1 in 
the neonatal mouse ovary at PND 3 and PND 5 is significantly greater than at 
earlier fetal and neonatal ages. 
 
Discussion 
 
Although issues with infertility might not entail life-threatening scenarios, 
there is still a great deal of relevance in conducting research in order to learn more 
about the potential processes and mechanisms that could contribute to this 
dysfunction. A major issue that correlates with infertility is the fact that once 
women establish their finite supply of viable ovaries, approximately around their 
time of birth, there is no action that can be taken to increase their supply or 
reverse permanent damage beyond that crucial developmental stage. It is for this 
reason that a great deal of research is currently being conducted in order to gain 
an in-depth understanding of the complex processes and pathways that are utilized 
throughout germ line development. If we can learn more about the intricate, 
interdependent processes that are occurring during this critical timeframe, then 
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perhaps we can gain a better understanding of how fertility dysfunctions occur 
and how we could eradicate or compensate for those dysfunctions in the future.  
Looking specifically at the role of hormone function throughout the 
process of germ line development, estrogen and progesterone are two hormones 
that are considered foundational contributors and are known to affect various 
aspects of development. Changes in levels of these hormones across development 
are known to be correlated with certain phases in the process of germ line 
development, acting as essential triggers for time-sensitive processes. However, 
excess amounts of these same hormones are known to have an equally negative 
effect on certain phases in this process, which, in turn, have a significant lasting 
effect on the overall developmental outcome.  
Previous research has demonstrated that increased levels of estrogen and 
progesterone in the fetal and neonatal mouse ovary have an inhibitory effect on 
the process of cyst breakdown (Chen et al., 2007). By inhibiting the breakdown of 
cysts into single primordial follicles, the overall percent of viable individual 
oocytes is drastically decreased. Instead of containing a large percentage of viable 
oocytes for future fertilization, the neonatal ovary is more likely to contain a more 
prominent number of MOF’s, which are thought to be unviable for future 
reproductive use. It is scenarios such as this that could contribute to increased 
chances for future infertility issues in females that were exposed to amplified 
levels of estrogen or progesterone at a critical time in reproductive development.  
    A great deal of research has been conducted revolving around the roles of 
estrogen and the negative effects that excess treatment of the hormone can have 
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on the process of germ line development. In comparison, the role of progesterone 
and the effects that excess levels of the hormone can have on developmental 
processes is less researched and less understood. We are less knowledgeable 
about the specific signaling pathways, receptors and affiliated proteins involved in 
progesterone signaling, which is why the research discussed here was conducted. 
We hoped to focus on specific progesterone signaling pathway receptors and 
proteins utilized across germ line development in mice in an attempt to gain 
information about how the overall role of progesterone might be dynamic, 
changing in function at different stages in reproductive development.    
Our research yielded a number of different results through experiments in 
immunocytochemistry and western blotting. Our results demonstrated that the 
PGRMC1 receptor and the interacting PAIRBP1 protein are both present in some 
capacity across germ line development in the fetal and neonatal mouse ovary, 
ranging from 15.5 dpc to PND 5. However, the expression of both of these 
progesterone signaling components were limited to the epithelial layer of the 
ovary. As constituents that are both thought to be actively involved in the 
progression and development of individual oocytes, we would have expected to 
see PGRMC1 and PAIRBP1 expressed, in one capacity or another, within the 
actual developing oocytes themselves. The spatial limitation of the receptor and 
protein could present a localization pattern found within developing fetal and 
neonatal mouse ovaries or the limitation could signify an error in the staining 
ability of the given antibodies. The lack of penetration of the antibody signal 
beyond the epithelial layer of the mouse ovary could be cognizant of a penetration 
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error of the appropriate antibody or an error in the whole mount antibody staining 
protocol that was utilized. Since the propidium iodide that was used to stain the 
nuclei of the cells within the ovary was capable of penetrating the entire ovary, it 
is most likely an issue with the anti-PGRMC1 and anti-PAIRBP1 antibodies that 
were utilized for this research. These experiments need to be repeated again, 
possibly altering the concentrations of the current primary antibodies or ordering 
a completely new lot of each antibody in order to continue testing the expression 
of PGRMC1 and PAIRBP1 in the mouse ovary across these crucial 
developmental stages.  
Unfortunately, the experiment conducted to test the expression of 
PGRMC2 in the mouse ovary from 15.5 dpc to PND 5 yielded no conclusive 
results. Unlike the epithelial expression characteristic of the experiments 
conducted with PGRMC1 and PAIRBP1, PGRMC2 was not detected in the fetal 
or neonatal mouse ovary. Previous studies in the Pepling Lab detected PGRMC2 
at 15.5 dpc, using the same antibody and technique that was used here, so these 
results were extremely unexpected and unexplainable. According to the results 
obtained here, PGRMC2 is not expressed in the developing ovary and therefore 
could not play a role in progesterone signaling pathways in the mouse ovary. If 
PGRMC2 were not expressed in the developing mouse ovary, then all 
progesterone signals entering the cell at the membrane level would have to be 
utilizing the PGRMC1 signaling pathway, which seems questionable. However, if 
certain progesterone signaling pathways, such as the PGRCM2 pathway, were not 
active during hormone treatments in which the ovaries are exposed to excess 
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amounts of progesterone, would that affect the amount of progesterone that is able 
to signal cells to inhibit cyst breakdown?  
In terms of the PGRMC2 immunocytochemistry experiment, it is more 
likely that there was some error in the experimental method used. More 
knowledge needs to be obtained to learn how the previous experiment that 
successfully demonstrated the expression of PGRMC2 in the fetal and neonatal 
mouse ovary was conducted. This experiment needs to be repeated after obtaining 
that knowledge and certain aspects of the protocol will need to be altered. Perhaps 
a change in the corresponding anti-PGRMC2 primary or secondary antibody 
concentration needs to be altered in order for the antibody to penetrate the entire 
mouse ovary.  
Overall, the results of the immunocytochemistry experiments did not 
provide any conclusive data. More experiments similar in nature to the 
experiments conducted in this research study will need to be altered and repeated 
in the hopes that more conclusive results can be obtained. The only result that 
could potentially support a current theory is the overlapping localization of both 
PGRMC1 and PAIRBP1 in the fetal and neonatal mouse ovary. The interaction 
between this membrane receptor and protein is not well understood, but thought 
to be necessary in order for the PGRMC1-progesterone signaling pathway to 
function properly, so it is logical to assume that these two progesterone signaling 
pathway components are co-localizing to the same region of the mouse ovary.  
The results obtained from western blotting experiments yielded variable 
data, as well. Our results demonstrated that PGRMC1 is expressed at relatively 
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constant levels in the mouse ovary across germ line development. According to 
the role that PGRMC1 plays in the progesterone signaling pathway, we would not 
expect the membrane receptor to be present at consistent levels from 15.5 dpc to 
PND 5. Given progesterone’s inhibitory function in cyst breakdown, perhaps we 
would expect progesterone, and therefore PGRMC1, to be expressed at decreased 
levels during the timeframe in germ line development when cyst breakdown is 
thought to occur, from approximately 17.5 dpc to PND 5. However, according to 
the western blot results, PGRMC1 is still strongly expressed in ovaries at these 
crucial ages. These results could raise further questions about the role of 
PGRMC1 in the progesterone signaling pathway in the ovary across fetal and 
neonatal mouse development. Perhaps more research needs to be conducted in 
order to determine the limitations and functions of this membrane receptor, which 
might fulfill additional functions that we are not yet aware of. The constant 
expression of PGRMC1 in the mouse ovary from 15.5 dpc to PND 5 could also be 
a result of several possible errors in the western blot protocol and technique. For 
example, perhaps more ovary extract sample was loaded into the wells at several 
of the ages, such as PND 1 and PND 3, which could affect the intensity of the 
bands upon detection and, in turn, alter the interpretation of the results. This is 
why re-probing with GAPDH is often performed in order to account for 
discrepancies such as this. Re-probing with the GAPDH loading control informed 
us that further tests need to be conducted using PGRMC1 in order to validate the 
expression of this receptor across germ line development.  
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Results from the western blot testing for the presence and intensity of 
PGRMC2 across germ line development were also unexpected. Even though a 
variety of antibody dilutions were used and several different incubation methods 
were tested, we did not find any expression of PGRMC2 in the fetal and neonatal 
mouse ovary from 15.5 dpc to PND 5. No bands of interest were detected at any 
of the developmental ages tested. Several different PGRMC2 antibodies were 
tested and a number of alterations were made to the western blot protocol in an 
attempt to detect PGRMC2, but PGRMC2 did not appear to be expressed across 
any of the experimental trials. These results also align with the results obtained 
from the immunocytochemistry experiments, which showed no detection of 
PGRMC2 via antibody staining. The complete lack of PGRMC2 detection in both 
experiments strengthens the argument that PGRMC2 is not functioning in the 
process of germ line development in the capacity that we had anticipated. Perhaps 
PGRMC2 is not playing a role in germ line development directly within the fetal 
and neonatal mouse ovary, but the membrane receptor is instead playing an 
indirect role. This could explain why PGRMC2 is not directly expressed in the 
mouse ovary across this critical developmental time period.  
There could be several errors in the western blot protocol and technique 
used, though, which could explain the unexpected results for PGRMC2 
expression in the fetal and neonatal mouse ovary. Two different PGRMC2 
antibodies, obtained from two different biotechnology companies, were tested, 
which leads us to believe that the lack of detectable protein signal is not a result of 
dysfunctional antibodies However, there could have been errors in the method 
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that was used to block insignificant bands from detection on the transfer 
membrane. One of the primary PGRMC2 antibodies that was used for a number 
of western blot experiments was made in goat. Since this antibody was made in 
goat and goats are closely related to cows, the chances of a cross-reaction between 
a blocking buffer containing milk and a secondary anti-goat antibody are thought 
to be increased. In order to ensure that any insignificant bands would be properly 
blocked, it was recommended that we substitute the 5% non-fat dry milk with 
goat serum. However, this alteration in the protocol led to several errors in the 
procedure. An appropriate amount of goat serum was not substituted into the 
blocking buffer solution, with only 50 µL of goat serum being added to each liter 
of blocking buffer instead of the 5 mL of goat serum that would be necessary in 
order to equal 5% of the overall blocking buffer solution volume. Adding such a 
small amount of goat serum in comparison to the remainder of the solution 
components could easily affect the results of each western blot that the blocking 
buffer was used in. Also, we recently learned about a contradicting theory 
recommending that when using primary antibodies made in goat for a western 
blot, a serum corresponding to the secondary anti-goat antibody should be used 
instead. For example, instead of substituting the 5% non-fat dry milk with goat 
serum each time blocking buffer solution was made, we should have used rabbit 
serum as a substitute instead, seeing as the secondary anti-goat antibody was 
made in rabbit. Upon first considering these discrepancies, we thought that 
perhaps altering these steps in the western blot protocol would yield different, or 
even more conclusive, results. However, the discrepancies discussed above would 
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be thought to cause insufficient blocking of insignificant proteins, but the major 
issue in this research was the complete lack of detectable PGRMC2 signal. For 
this reason, more thought needs to be given to these technical discrepancies and 
further experimental tests need to be conducted in order to determine their effects.  
The results obtained from the western blots investigating PAIRBP1 
expression in the mouse ovary across germ line development were quite 
interesting. Given the significant interaction that is thought to be present between 
PGRMC1 and PAIRBP1 in the PGRMC1-progesterone signaling pathway, we 
would have expected to see a similar detection pattern for PAIRBP1 bands of 
interest from 15.5 dpc to PND 5. However, PAIRBP1 appeared to be only faintly 
detected at 15.5 dpc, and then continually gained band intensity as germ line 
development proceeded. The western blot results suggested that the protein 
exhibits a definitive expression trend, where PAIRBP1 expression directly 
increases as the age of the mouse ovaries increase.  
Perhaps this difference in detection between PGRMC1 and PAIRBP1 
could have something to do with the anti-apoptotic function that PAIRBP1 is 
thought to be involved in in the PGRMC1-progesterone signaling pathway. 
Levels of PAIRBP1 expression could be lower in the days of fetal development 
leading up to the commencement of germ cell death, or apoptosis, which is 
thought to begin at approximately 18 dpc. Lower levels of this protein could act 
as some sort of trigger that initiates the apoptotic process. After the initiation of 
germ cell death, PAIRBP1 expression could strengthen. This could happen in 
order to ensure that the PGRMC1-progesterone signaling pathways anti-apoptotic 
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function is serving to terminate the apoptotic phase of germ line development, 
which ends at approximately PND 4.5. In order for this PAIRBP1 expression 
pattern to be valid, it would require some type of delay between the time at which 
PAIRBP1 levels change and the subsequent germ line development phase is 
initiated. A wider range of fetal and neonatal mouse ages would need to be tested 
in order to further explore this idea.    
There are several technical errors that could account for the interesting 
PAIRBP1 detection results that were obtained. Unfortunately, not a great deal of 
time was able to be dedicated to investigating this particular protein so, in order to 
validate the results shown in Figure 12, a number of western blot experiments 
would need to be repeated using the same antibody dilution and incubation 
procedures. Also, the differences in the band intensities across each of the 5 ages 
tested could be a result of unequal loading of samples into each well upon the 
initial running of the gel. If a smaller amount of sample from 15.5 dpc or 17.5 dpc 
was loaded than sample from several of the postnatal ages, then that could explain 
the weaker band detection at those fetal ages.  
Overall, the results obtained from the western blot experiments yielded a 
number of different unexpected, but intriguing results. The complete lack of 
detection of PGRMC2 expression in the fetal and neonatal mouse ovary across 
germ line development aligns with the results obtained in the 
immunocytochemistry experiment, but will obviously require further research 
since the complete non-existence of PGRMC2 in the mouse ovary at any point in 
germ line development is not likely. The protein blot detection results for 
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PGRMC1 and PAIRBP1 do not correlate in the same manner as was seen in the 
immunocytochemistry results for this membrane receptor and protein. Perhaps 
PGRMC1 is required for a number of other functions that occur throughout the 
process of germ-line development, whereas PAIRBP1 is limited to playing a role 
in the PGRMC1-progesterone signaling pathway’s anti-apoptotic function. Even 
so, the PAIRBP1 expression pattern that was detected by changes in band 
intensity from 15.5 dpc to PND 5 does not precisely align with the germ cell death 
timeframe that is shown in Figure 1, so a great deal more research will need to be 
conducted in order to learn more about this protein individually, as well as its 
interaction with PGRMC1.  
 
Future Work 
 
Given the variability of the results, as well as the unsuccessful completion 
of several of the experiments, there is a great deal of future work that can be 
conducted on this topic and the individual components of this research. Each of 
the experiments conducted in this research study could be repeated, or altered and 
repeated, to gain more conclusive and valid results. The overall age range used for 
the immunocytochemistry and western blot experiments could be expanded to 
include fetal ovaries at 13.5 dpc, as well as post natal ovaries at PND 7.  Even 
though the crucial timeframe during which cyst breakdown and apoptosis is 
accounted for throughout this research study, it could always be beneficial to 
obtain more results and gain more information across a wider age range   
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    Since some of the experimental methods used, such as the western blot, 
required a variety of alterations in antibody dilutions, perhaps a different 
experimental technique called a dot blot could be used. Dot blots could be used as 
a simplification of the western blot technique, where ranges of different primary 
antibody dilutions are tested on the sample of interest. This could be beneficial to 
determine which antibody dilution will yield the best detectable band before 
running an entire western blot with a number of different samples. Completing 
dot blots prior to future western blots could help ensure that the antibody of 
interest is functioning properly and at an optimal level before proceeding on to 
future experimental tests.  
The incorporation of organ culture experiments into further research on 
this topic could be extremely beneficial in terms of investigating how changes in 
the functioning of PGRMC1, PGRMC2 and/or PAIRBP1 have a lasting effect on 
the progression of germ line development in the mouse ovary. Having the ability 
to manipulate these signaling pathways via function-blocking antibodies would 
allow us to analyze the direct effects that are had on the formation of primordial 
follicles. Organ cultures could be conducted using ovaries at 13.5 dpc, 15.5 dpc 
and PND 1, which would each be grown in culture for 5 days. Upon completion 
of each function-blocking organ culture the ovaries, now 17.5 dpc, PND 1 and 
PND 5, could be analyzed via immunocytochemistry using the same whole mount 
antibody staining procedure that was used in this research study. Once the treated 
ovaries were stained it would be possible to count and calculate the number of 
individual oocytes in each ovary as a determinant of overall follicle development. 
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The ability to calculate the approximate overall success of cyst breakdown and, in 
turn follicle development, via oocyte counting would be extremely valuable in 
quantifying the importance of progesterone signaling pathway components, such 
as PGRMC1, PGRMC2 and PAIRBP1. Incorporating these types of experiments 
into future research would bring an entirely new and significant dimension to this 
topic of study.    
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Appendices 
 
Figures 
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